53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersPeter Bouwman, Jos Jonkers|Nature Structural & Molecular Biology|2010Cited by 1k
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance PathwaysMirjam C. Boelens, Andy J. Minn, Tony J. Wu et al.|Cell|2014Cited by 798
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerRowan Miller, Lucy Yates, Alexandra Léary et al.|Annals of Oncology|2020Cited by 478
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Brian Dougherty et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Cristina Cruz et al.|EMBO Molecular Medicine|2018Cited by 271